FDA Approves Ropeginterferon Alfa-2b-Njft for Polycythemia Vera

The FDA has approved ropeginterferon alfa-2b-njft (BesremiĀ®, PharmaEssentia) for patients with polycythemia vera, marking the first approval of interferon therapy specifically for patients with polycythemia vera and the first treatment for all patients with polycythemia vera, regardless of their prior treatment history. "Ropeginterferon alfa-2b is a novel long-acting monopegylated IFN-alpha-2b," wrote Heinz Gisslinger, MD, Professor of Hematology at the Medical University of Vienna, Austria, and...

Continue reading

Copyright Ā© 2022 Oncology Data Advisor. All rights reserved.